The company has reported a total income of Rs.4298.02 crores during the period ended June 30, 2021, as compared to Rs.3831.74 crores during the period ended March 31, 2021. For the period ended June 30, 2020, the total income stood at Rs 3571.14 crores.

The company has posted a net profit of Rs.542.46 crores for the period ended June 30, 2021, as against a net profit of Rs.460.36 crores for the period ended March 31, 2021. For the period ended June 30, 2020, the company had posted a profit of Rs 106.90 crore.The company has reported EPS of Rs.11.91 for the period ended June 30, 2021, as compared to Rs.10.11 for the period ended March 31, 2021. The EPS for the period ended June 30, 2020, stood at Rs 2.35.

Commenting on the results, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, "While the quarter's profits were bolstered by the Boehringer Ingelheim MEK program income, despite a tough operating environment, we see substantial room for growth. We remain committed to growing our US business both with our inline products as well as the ramp-up of Albuterol and Brovana, to continue above-market growth in India, and ensure growth in every part of the business. We see meaningful uplift in the second half and remain focused on our journey of expanding margins through driving strong double-digit revenue growth and optimizing costs while ensuring the safety of our people and the highest standards of compliance."